Combination of Nivolumab and Ipilimumab Improved Overall Survival For Advanced Melanoma Patients

?WASHINGTON — Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab and appeared to have more favorable survival outcomes compared with those who received nivolumab, according to results from the phase III CheckMate 067 clinical trial presented here at […]

TERT Inhibitors Show Potential in Treatment of Uncommon Type of Melanoma

Scientists reported a significant genetic association linked to an aggressive form of melanoma in a study (“Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma”) published in Genome Research.

IDO Inhibitor Increases Pembrolizumab Response in Melanoma

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate (ORR) of 52% in patients with advanced melanoma, according to findings from a phase II trial reported at the 2017 AACR Annual Meeting.

Common Cold Virus Improves Response with Immunotherapy in Advanced Melanoma

Half of patients with advanced melanoma responded to a novel combination treatment consisting of the common cold virus with an immune checkpoint inhibitor, in a recent phase Ib clinical trial presented April 4 at the American Association for Cancer Research (AACR) Annual Meeting.

Cancer in the News

Feature Articles

Adding the IDO-pathway Inhibitor Indoximod to Pembrolizumab Improved Melanoma Response Rate

WASHINGTON, D.C.—Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab increased the proportion of patients with advanced melanoma who responded to treatment compared with previously reported response rates for pembrolizumab monotherapy, according to interim results from a phase I/II clinical trial presented at the AACR Annual Meeting 2017, April 1-5 (Abstract CT117).

Read the full story

Posted in Melanoma In The News, Clinical Trials

Survival in Advanced Melanoma With Ipilimumab at 10 mg/kg vs 3 mg/kg

In a phase III trial reported by Ascierto et al in The Lancet Oncology, treatment with ipilimumab (Yervoy) at 10 mg/kg vs 3 mg/kg resulted in improved overall survival in patients with advanced unresectable or metastatic melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Indoximod plus pembrolizumab prompts response in advanced melanoma

The addition of investigational immunotherapy indoximod to pembrolizumab conferred superior response rates in patients with advanced melanoma, according to interim results of a phase 2 clinical trial presented at the American Association for Cancer Research Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Drug Combo Boosts Response Rate by Half in Melanoma

WASHINGTON — Combining two immune checkpoint inhibitors led to a 50% increase in response rate in advanced melanoma, as compared with the historical rate that led to FDA approval of one of the drugs, investigators reported here.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories